CEO
Cohance Lifesciences Limited
Equibles does not estimate personal net worth.
Yandir is recorded as CEO at Cohance Lifesciences Limited. Yandir has spoken on 3 earnings calls across 1 company, most recently for Cohance Lifesciences Limited on November 6, 2026. Cohance Lifesciences Limited is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
“I will build on Umang's comments and focus on the operating progress across small molecules, ABCs, and nucleic acids. ParmaTDMO led our sequential recovery in Q2 with revenues growth of 34.5% quarter on quarter, primarily driven by a higher contribution from small molecules.”
“I will cover the operational performance across small molecules, the ADT payload business, NG Bio, and Sapala. As Humong mentioned, Q1 was affected by customer shipment phasing resulting in softer revenue, as guided earlier.”
“The pharmacy GMO business reported revenue of 8.89 billion rupees for FY26. Adjusting for the stocking impact in the two large commercial molecules, the business delivered an underlying growth of early single digits.”
Cohance Lifesciences Limited
CEO
Transcript header (unverified)
Cohance Lifesciences Limited
Drug Manufacturers - Specialty & Generic · Healthcare
CEO
Earnings Call for the Quarter Ended September 30, 2026
Cohance Lifesciences Limited
Earnings Call
Cohance Lifesciences Limited
Earnings Call for the Quarter Ended March 31, 2026
Cohance Lifesciences Limited
